Basilea outlines IDWeek 2026 data presentations across three anti-infective medicines
Fosmanogepix and manogepix presentations include paediatric expanded-access experience and activity against Candida auris, alongside isavuconazole and ceftobiprole studies. IN BRIEFKEY TAKEAWAYSFAQs Basilea Pharmaceutica Ltd has announced presentations of data on fosmanogepix, isavuconazole (Cresemba) and ceftobiprole (Zevtera) at IDWeek 2026 in … Read the full press release →
Free plan · Plus CA$29 or Pro CA$99/month


